HERE’S TO 5 YEARS SINCE INITIAL FDA APPROVAL FOR ADULT PATIENTS (18+ YEARS) WITH UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS.^a

^a FDA approved since 2017 for adults, 2019 for teens (aged 12-17 years) and 2020 for children (aged 6-11 years) and 2022 for young children (aged 6 months-5 years) with uncontrolled moderate-to-severe atopic dermatitis.

DUP.22.06.0381

A BREAKTHROUGH BIOLOGIC
TREATMENT FOR ECZEMA

DUPIXENT helps block a key source of inflammation that can cause eczema

DUPIXENT helps you stay ahead of symptoms by continuously treating eczema, even between flare-ups

Normal Skin

A healthy immune
system produces little to
no inflammation on the
skin.

A close up look of skin cells with Uncontrolled Moderate-to-Severe Eczema (Atopic Dermatitis)

Skin With Eczema

The immune system in
those with eczema may
produce more
inflammation than
normal, contributing to
itching, rashes, and
flare-ups on the surface
of the skin.

Close view of skin cells treated with Dupixent® (dupilumab) for Uncontrolled Moderate-to-Severe Eczema (Atopic Dermatitis)

Eczema Skin Treated
With DUPIXENT

DUPIXENT may help reduce this inflammation in those with uncontrolled moderate-to-severe eczema for noticeably clearer skin and less itch.

A DIFFERENCE
INSIDE AND OUT

A BIOLOGIC that continuously treats eczema from the inside, even between flare-ups
NOT A STEROID or immunosuppressant
TREATS BOTH moderate and severe eczema when topical prescription therapies aren't enough
DOES NOT REQUIRE initial or routine bloodwork (according to Prescribing Information)
Can be used with or without topical corticosteroids
IS NOT TAKEN DAILY

SEE HOW DUPIXENT WORKS TO TREAT ECZEMA

How Dupixent® (dupilumab) Works to Target a Source of Underlying Inflammation in Moderate-to-Severe Eczema (Atopic Dermatitis) Video

Chapters

Transcript

DUPIXENT TARGETS A SOURCE OF UNDERLYING INFLAMMATION

How It Works

INDICATION

DUPIXENT is a prescription medicine used to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age.

Important Safety Information

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Please see Important Safety Information throughout video and accompanying full Prescribing Information, including Patient Information.

Atopic dermatitis, the most common form of eczema, can be caused in part by constant inflammation in your body, which can lead to dry, flaky, itchy skin and rash on the surface of your skin. Moderate-to-severe atopic dermatitis can be difficult to manage.

Patients with atopic dermatitis can have some skin with rash and some skin without rash. But even skin without rash may have ongoing, underlying inflammation. This is because the immune system is overactive.

The overactive immune response in eczema (atopic dermatitis or AD) involves two main parts: A weak skin barrier and underlying internal inflammation. With atopic dermatitis, outside substances such as bacteria, viruses, and allergens may enter the weak outer layer of skin more easily than in healthy skin.

As these outside substances enter the body, a signal is sent to the immune system, causing some immune cells in the second layer of skin to overreact.

Even when these outside substances are no longer present, this overreaction continues.

Cytokines, small proteins that affect communication between cells, are part of the inflammatory signal that can cause the symptoms that patients with atopic dermatitis experience.

DUPIXENT works under the skin. When DUPIXENT attaches to certain immune cells, it inhibits an inflammatory signal from these specific cells that contributes to causing atopic dermatitis.

DUPIXENT may help reduce the rash you see and feel on your skin and targets an underlying source of inflammation that could be a root cause of your eczema.

In two, 16-week clinical studies with DUPIXENT

Almost 4 times more adult patients at 16 weeks taking DUPIXENT saw clear or almost clear skin (37% vs 9% not taking DUPIXENT)
Adult patients experienced significant itch reduction at 16 weeks (38% vs 11% not taking DUPIXENT), some as early as 2 weeks (10% vs 2% not taking DUPIXENT)

DUPIXENT can cause serious side effects, including allergic reactions that can sometimes be severe, eye problems, and joint aches and pain.

The most common side effects in patients with eczema include injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, dry eye, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Patient Information.

The relationship between how DUPIXENT works in your body and its clinical effects is unknown.

So, ask your doctor if DUPIXENT could help heal your skin from within.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Patient Information.

Important Safety Information and Indication

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

have eye problems.
have a parasitic (helminth) infection.
are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.
are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
- A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/.
are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical or inhaled corticosteroid medicines or if you have atopic dermatitis and asthma and use an asthma medicine. Do not change or stop your corticosteroid medicine or other asthma medicine without talking to your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.

DUPIXENT can cause serious side effects, including:

Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue, or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area.
Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an eye exam if needed.
Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying full accompanying full Prescribing Information including Patient Information.